Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Stock Gets Price Target Cut from Truist Financial

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) had its target price reduced by Truist Financial from $25.00 to $24.00 in a report issued on Monday,Benzinga reports. Truist Financial currently has a hold rating on the stock.

Other research analysts have also issued reports about the stock. Berenberg Bank set a $24.00 price target on shares of Fresenius Medical Care AG & Co. KGaA in a research note on Tuesday, September 29th. Zacks Research upgraded Fresenius Medical Care AG & Co. KGaA from a “strong sell” rating to a “hold” rating in a research note on Monday, July 6th. Sanford C. Bernstein boosted their price objective on Fresenius Medical Care AG & Co. KGaA from $25.50 to $25.80 and gave the stock a “market perform” rating in a research note on Thursday, August 6th. Weiss Ratings raised Fresenius Medical Care AG & Co. KGaA from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, October 8th. Finally, Citigroup reissued a “neutral” rating on shares of Fresenius Medical Care AG & Co. KGaA in a report on Friday, July 17th. Eight analysts have rated the stock with a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Reduce” and a consensus price target of $23.42.

Fresenius Medical Care AG & Co. KGaA Stock Performance

NYSE:FMS opened at $21.57 on Monday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 1.07. The company has a fifty day moving average of $22.73 and a two-hundred day moving average of $22.89. The stock has a market capitalization of $11.58 billion, a PE ratio of 11.17, a P/E/G ratio of 3.90 and a beta of 0.74. Fresenius Medical Care AG & Co. KGaA has a fifty-two week low of $20.02 and a fifty-two week high of $27.43.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last posted its quarterly earnings data on Monday, August 3rd. The company reported $0.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.62 by $0.04. Fresenius Medical Care AG & Co. KGaA had a net margin of 4.83% and a return on equity of 9.28%. The business had revenue of $5.55 billion for the quarter, compared to the consensus estimate of $5.48 billion. As a group, research analysts forecast that Fresenius Medical Care AG & Co. KGaA will post 2.25 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Fresenius Medical Care AG & Co. KGaA

Several institutional investors and hedge funds have recently added to or reduced their stakes in FMS. Pzena Investment Management LLC raised its position in shares of Fresenius Medical Care AG & Co. KGaA by 2.0% in the first quarter. Pzena Investment Management LLC now owns 15,052,822 shares of the company’s stock valued at $339,592,000 after buying an additional 299,986 shares during the last quarter. Moran Wealth Management LLC boosted its position in Fresenius Medical Care AG & Co. KGaA by 31.5% during the first quarter. Moran Wealth Management LLC now owns 347,773 shares of the company’s stock worth $7,846,000 after acquiring an additional 83,311 shares during the last quarter. Quantinno Capital Management LP boosted its position in Fresenius Medical Care AG & Co. KGaA by 15.7% during the first quarter. Quantinno Capital Management LP now owns 341,343 shares of the company’s stock worth $7,701,000 after acquiring an additional 46,428 shares during the last quarter. Royal Bank of Canada boosted its position in Fresenius Medical Care AG & Co. KGaA by 479.2% during the first quarter. Royal Bank of Canada now owns 216,861 shares of the company’s stock worth $4,893,000 after acquiring an additional 179,418 shares during the last quarter. Finally, Assetmark Inc. grew its stake in Fresenius Medical Care AG & Co. KGaA by 190.7% during the 1st quarter. Assetmark Inc. now owns 132,320 shares of the company’s stock valued at $2,985,000 after acquiring an additional 86,798 shares in the last quarter. Institutional investors and hedge funds own 8.37% of the company’s stock.

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG & Co KGaA is a Germany-based health care company focused on the treatment of chronic kidney disease and kidney failure. The company provides dialysis care through a global network of outpatient clinics and supports patients with related medical services, including vascular access care, laboratory services and care coordination.

In addition to operating dialysis facilities, Fresenius Medical Care develops and manufactures products used in dialysis treatment.